SCHEMBL2534951

SCHEMBL2534951

COC(=O)c1cc(Cl)ccc1NC(=O)C=P(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 2/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 4/20 0.43
GAA P10253 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HPGD P15428 3/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
ABL1 P00519 1/20 0.42
NPC1 O15118 1/20 0.42
EGFR P00533 1/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
SERPINE1 P05121 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4736951 0.78 ABL1 (0.49) SMN1; SMN2HTTKDM4EHSD17B10ALDH1A1
SCHEMBL418156 0.75 ALDH1A1 (0.59) SMN1; SMN2KDM4EALDH1A1GAAHPGD
SCHEMBL418157 0.75 ALDH1A1 (0.59) SMN1; SMN2KDM4EALDH1A1GAAHPGD
SCHEMBL3784326 0.74 KDM4E (0.62) SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA
SCHEMBL5928677 0.74 KDM4E (0.71) SMN1; SMN2HTTKDM4EHSD17B10ALDH1A1
SCHEMBL420830 0.74 EGFR (0.57) SMN1; SMN2KDM4EALDH1A1GAACYP1A2
SCHEMBL420831 0.74 EGFR (0.57) SMN1; SMN2KDM4EALDH1A1GAACYP1A2
SCHEMBL420708 0.72 SERPINE1 (0.47) SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA
SCHEMBL420688 0.72 SLC6A4 (0.62) SMN1; SMN2HTTKDM4EALDH1A1GAA
SCHEMBL1095126 0.72 CASP3 (0.58) SMN1; SMN2KDM4EGAACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND MC4R, MC5R, MC2R SMN1; SMN2 398/4885HTT 1631/4885KDM4E 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.